FY2027 Q1 results (revenue, gross margin, cash generation)
קריטי ספקית חומרים מרוכבים מתקדמים לתעופה/חלל; פרי-פרג, דבקים, חומרי ablative לטילים ומבנים.
עובד אם ביקוש תוכניתי בתעופה ובטילים הופך להכנסה רווחית ובת-קיימא ולתזרים חופשי.
- מצב התזה
- חזקה פיננסית ונתמכת-תוכניות, אך רגישה-לולואציה ומרוכזת תפעולית.
- תפקיד בתיק
- עוגן תעשייתי/תעופתי איכותי, עם סיכון ולואציה וריכוזיות.
- מסגרת פעולה
- החזקה / מעקב (Hold / Monitor)
- טריגר לסקירה
- תוצאות FY2027 Q1, צבר, מכירות GE/Aerojet, מרווח גולמי, תקציב המפעל החדש ועדכוני ATM.
- גישת הערכה
- Scenario-based; no single price target
מצריך סקירה אנושית שווי / משקל: לא מחושב
מה חייב לקרות
- FY2027 confirms FY2026/Q4 durability
- Backlog converts at attractive margins
- GE/MRAS and missile programs progress; gross margin stays around 30%+
- New-plant ROIC becomes credible; ATM issuance stays controlled
- Park-manufactured ablatives outgrow low-markup C2(R)B fabric pass-through
מה יכול לשבור את התזה
- Material GE/MRAS or Aerojet/L3Harris/PAC-3 revenue deterioration
- Persistent backlog conversion failure
- Gross margin below 28% without a credible recovery path
- Growth dominated by low-markup C2(R)B fabric rather than Park-manufactured content
- Loss of qualification, certification, sole-source position, or customer trust
- Persistent ArianeGroup/C2(R)B or other raw-material bottlenecks
- Material new-plant overrun, delay, underutilization, or unclear ROIC
- ATM dilution without commensurate per-share value creation
- Dividend uncovered by normalized FCF after capex
- Premium valuation despite weakening revenue, margin or cash-flow evidence
הקטליסטים הבאים
Q4 durability / run-rate confirmation
קריטי GE/MRAS program sales toward $34M-$38M FY2027 estimate
קריטי Aerojet/L3Harris/PAC-3 orders and Park-manufactured ablative growth
גבוה New-plant budget, timeline, funding and expected returns
גבוה ATM issuance and fully diluted share-count update
גבוה הסיכונים המרכזיים
Valuation multiple compression (demanding vs current earnings/FCF)
Customer/program concentration (GE/MRAS + Aerojet ~51% of FY2026; top five ~72%)
Margins deteriorate structurally or C2(R)B mix worsens
Raw-material/ArianeGroup bottlenecks and missed shipments
New-plant cost escalation, underutilization, or ATM dilution
Larger competitors or loss of qualification/certification/sole-source status
KPI למעקב
- FY2026 net sales
- $73.301M — +18%
- FY2026 gross margin
- 30.9% — strong improvement; durability unproven
- FY2026 operating earnings
- $13.500M — ~18.4% operating margin
- FY2026 net earnings
- $11.272M
- FY2026 operating cash flow
- $11.499M — capex $2.038M; directional FCF proxy ~$9.5M
- Cash and marketable securities
- $89.368M — no long-term debt
- Backlog
- ~$51.4M (2026-05-18) — visibility, not revenue
- FY2026 GE program sales
- $29.3M — FY2027 estimate $34M-$38M
- GE-related + Aerojet share of FY2026 sales
- ~51% — Q4 top five ~72%; concentration risk
- Q4 FY2026 net sales
- $24.187M — step-up quarter; not yet a proven run-rate
כללי פעולה — מסגרת, לא המלצה
הוספה (Add)
- Consider only when valuation resets or evidence strengthens materially
- FY2027 confirms durability; backlog converts at margin; gross margin ~30%+
- Normalized FCF covers the dividend; plant ROIC credible; ATM controlled; position size appropriate
- Do not add solely because PKE is high quality, has cash, or has a long dividend history
החזקה (Hold)
- Thesis intact; FY2026 improvement credible but not fully confirmed
- Financial quality strong; valuation plausible only under base/bull scenarios
- Position size appropriate
קיצוץ (Trim)
- Valuation prices sustained bull-case growth before proof
- Margins weaken; program catalysts slip; capex/ATM risk rises; position too large
- A trim can be risk management without thesis rejection
יציאה (Exit)
- Backlog fails to convert; FY2027 shows FY2026 was temporary
- Gross margin below 28% without a recovery path
- GE/Aerojet/PAC-3 demand weakens materially; key qualification/sole-source lost
- Plant capex destroys returns; dilution becomes material; valuation stays premium while earnings power deteriorates
שאלות פתוחות
Do FY2027 Q1/Q2 confirm FY2026 and Q4 durability?
קריטי How much of the ~$51.4M backlog converts, when, and at what margin?
קריטי Are FY2027 GE/MRAS sales tracking toward the $34M-$38M estimate?
קריטי How much revenue is Aerojet/L3Harris/PAC-3, and how much is Park-manufactured?
קריטי Final plant budget, timeline, funding, utilization threshold and ROIC?
קריטי Does normalized FCF cover the dividend after plant capex?
קריטי Will ATM issuance continue, and what is fully diluted share count?
קריטי Gross margin by product family, especially C2(R)B fabric vs Park ablatives
גבוה C2(R)B U.S. manufacturing agreement, ArianeGroup capacity and supply timing
גבוה Current valuation expectations versus FY2027 evidence
גבוה מקורות בריפו
נתיבים בריפו (מקור האמת) — לעיון, לא קישורים פעילים:
ai-context/company-briefs/pke-he.md companies/pke/dashboard.mdcompanies/pke/thesis.mdcompanies/pke/ic-memo.mdcompanies/pke/risks.mdcompanies/pke/catalysts.mdcompanies/pke/monitoring/README.mdcompanies/pke/working-notes.md
Derived from companies/pke/ — the repo is the source of truth. No price targets, no buy/sell recommendation. Q4 FY2026 was a step-up quarter and must not be annualized as a permanent run-rate. Track low-markup C2(R)B fabric pass-through separately from higher-margin Park-manufactured ablatives. Backlog and requirements contracts do not equal revenue; certifications and sole-source status are not permanent.